Interestingly, ICS discontinuation in COPD patients results in increased bronchial CD3+, CD4+, and CD8+, along with increased sputum total cell counts (Kunz et al., 2017), further demonstrating the local anti-inflammatory effect of ICS. This evidence concerns the gene CD4 and chronic obstructive pulmonary disease.